A federal court judge in Ohio denied Friday an attempt by the US Chamber of Commerce to immediately stop the Biden administration’s implementation of Medicare’s new drug price negotiation program.

The ruling was the first time a federal court has weighed in on the multiple lawsuits filed against the controversial program.

The chamber filed a lawsuit in June arguing that allowing Medicare to negotiate drug prices is unconstitutional for several reasons. It then asked for a preliminary injunction to halt the program by October 1, when drug makers have to agree to participate in the program.

“As to Plaintiffs’ motion for a preliminary injunction, they have demonstrated neither a strong likelihood of success nor irreparable harm,” wrote Judge Michael Newman of the US District Court for the Southern District of Ohio, in Dayton.

  • MirthfulAlembic@lemmy.world
    link
    fedilink
    English
    arrow-up
    4
    arrow-down
    7
    ·
    1 year ago

    This is patently false. Do some research on the clinical development process. Running trials is neither cheap nor easy. You can’t just go from lab to store shelves. You have to run phase 1, 2, and 3 studies to prove it is safe and works.

    I’m not arguing against being able to negotiate drug prices, by the way. The government should do that.

      • MirthfulAlembic@lemmy.world
        link
        fedilink
        English
        arrow-up
        1
        ·
        1 year ago

        I didn’t say that there isn’t publicly funded research. There is both public and private. The claim that private companies do nothing but package and manufacture is not in line with reality, however.